Production (Stage)
Scinai Immunotherapeutics Ltd.
SCNI
$2.72
$0.031.12%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -19.09% | 2.29% | 16.22% |
| Total Depreciation and Amortization | -- | -- | 84.23% | 161.40% | -28.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -347.86% | 115.56% | 656.55% |
| Change in Net Operating Assets | -- | -- | -24.38% | -1,586.50% | -532.19% |
| Cash from Operations | -- | -- | -96.69% | -27.03% | 5.20% |
| Capital Expenditure | -- | -- | -31.07% | 30.83% | 104.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -31.07% | 31.83% | 104.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -86.60% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 875.71% | -86.86% | -101.75% |
| Foreign Exchange rate Adjustments | -- | -- | 67.58% | 77.83% | -284.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -51.03% | -3,513.69% | -887.45% |